Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yingshan Han, Thibault Mesplède & Mark A. Wainberg. (2017) Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opinion on Investigational Drugs 26:11, pages 1207-1213.
Read now
Read now
Mario Cruciani & Marina Malena. (2015) Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations. Patient Preference and Adherence 9, pages 299-310.
Read now
Read now
Articles from other publishers (37)
Murat Sayan, Figen Sarigul Yildirim, Sila Akhan, Ilkay Karaoglan & Halis Akalin. (2022) Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis
in Treatment-Naive, INSTI Free Antiretroviral-Experienced and
INSTI-Experienced Turkish Patients Infected with HIV-1. Current HIV Research 20:2, pages 184-192.
Crossref
Crossref
Agete Tadewos Hirigo, Selamawit Gutema, Aberash Eifa & Worku Ketema. (2022) Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus. SAGE Open Medical Case Reports 10, pages 2050313X2210794.
Crossref
Crossref
Adam Leonard, Janessa Broussard, Natalie Wilson & Carol Dawson-Rose. (2022) Cabotegravir and Rilpivirine: A Long-Acting Injectable Antiretroviral Treatment for Human Immunodeficiency Virus. The Journal for Nurse Practitioners 18:1, pages 17-21.
Crossref
Crossref
Nokuzola Mbhele, Benjamin Chimukangara & Michelle Gordon. (2021) HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. International Journal of Antimicrobial Agents 57:5, pages 106343.
Crossref
Crossref
Hanh T Pham, Brunna M Alves, Sunbin Yoo, Meng A Xiao, Jing Leng, Peter K Quashie, Esmeralda A Soares, Jean-Pierre Routy, Marcelo A Soares & Thibault Mesplède. (2021) Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir. Journal of Antimicrobial Chemotherapy 76:3, pages 639-647.
Crossref
Crossref
Aurelio Orta-Resendiz, Roberto A. Rodriguez-Diaz, Luis A. Angulo-Medina, Mario Hernandez-Flores & Luis E. Soto-Ramirez. (2020) HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study. AIDS Research and Therapy 17:1.
Crossref
Crossref
Agnieszka Kolakowska, Anaenza Freire Maresca, Intira Jeannie Collins & Johann Cailhol. (2019) Update on Adverse Effects of HIV Integrase Inhibitors. Current Treatment Options in Infectious Diseases 11:4, pages 372-387.
Crossref
Crossref
Jennifer Fusco, Cassidy Henegar, Evelyn Byrd Quinlivan, Vani Vannappagari, Michael Aboud, Kimberly Smith & Gregory Fusco. (2019) Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. Current HIV Research 17:4, pages 266-276.
Crossref
Crossref
Li-Li Yang, Qi Li, Li-Bo Zhou & Shu-Qing Chen. (2019) Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. International Journal of Antimicrobial Agents 54:5, pages 547-555.
Crossref
Crossref
Samantha Gerlach, Partha Chandra, Upal Roy, Sunithi Gunasekera, Ulf Göransson, William Wimley, Stephen Braun & Debasis Mondal. (2019) The Membrane-Active Phytopeptide Cycloviolacin O2 Simultaneously Targets HIV-1-infected Cells and Infectious Viral Particles to Potentiate the Efficacy of Antiretroviral Drugs. Medicines 6:1, pages 33.
Crossref
Crossref
Wooyong JeongIn Young JungHeun ChoiJung Ho KimHye SeongJin Young AhnSu Jin JeongNam Su KuJune Myung KimJun Yong Choi. (2019) Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea. AIDS Research and Human Retroviruses 35:2, pages 213-216.
Crossref
Crossref
Najwa Alaoui, Moulay Abdelaziz El Alaoui, Nadia Touil, Hicham El Annaz, Marouane Melloul, Reda Tagajdid, Naoufal Hjira, Mohamed Boui, El Mostapha El Fahime & Saad Mrani. (2018) Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco. BMC Research Notes 11:1.
Crossref
Crossref
Maureen Oliveira, Ruxandra-Ilinca Ibanescu, Kaitlin Anstett, Thibault Mésplède, Jean-Pierre Routy, Marjorie A. Robbins & Bluma G. Brenner. (2018) Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 15:1.
Crossref
Crossref
Bluma G. Brenner & Jean-Guy Baril. (2017) Limiting cardiovascular events associated with HIV and antiretroviral therapy. AIDS 31:18, pages 2551-2553.
Crossref
Crossref
Bluma G. Brenner, Ruxandra-Ilinca Ibanescu, Maureen Oliveira, Michel Roger, Isabelle Hardy, Jean-Pierre Routy, Fred Kyeyune, Miguel E. Quiñones-Mateu & Mark A. Wainberg. (2017) HIV-1 strains belonging to large phylogenetic clusters show accelerated
escape from integrase inhibitors in cell culture compared with viral isolates from
singleton/small clusters. Journal of Antimicrobial Chemotherapy 72:8, pages 2171-2183.
Crossref
Crossref
Emmanuel Ndashimye. (2017) High Time to Start Human Immunodeficiency Virus Type 1–Infected Patients on Integrase Inhibitors in Sub-Saharan Africa. The Journal of Infectious Diseases 216:2, pages 283-284.
Crossref
Crossref
Iris ChenYinfeng ZhangVanessa CummingsGavin A. ClohertyMatthew ConnorGeetha BeauchampSam GriffithScott RoseJoel GallantHyman M. ScottSteven ShoptawCarlos del RioIrene KuoSharon MannheimerHong-Van TieuChristopher B. HurtSheldon D. FieldsDarrell P. WheelerKenneth H. MayerBeryl A. KoblinSusan H. Eshleman. (2017) Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States. AIDS Research and Human Retroviruses 33:7, pages 745-748.
Crossref
Crossref
Bluma G. Brenner & Mark A. Wainberg. (2017) Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Research 239, pages 1-9.
Crossref
Crossref
Edward J Mills, Steve Kanters & Nathan Ford. (2017) The comparative effectiveness of antiretroviral therapies for HIV: evidence to inform precision public health. Journal of Comparative Effectiveness Research 6:2, pages 85-87.
Crossref
Crossref
Alberto Enrico Maraolo. (2017) HIV-1 Integrase Inhibitors Resistance: Update of the Current Literature. Current Treatment Options in Infectious Diseases 9:1, pages 44-51.
Crossref
Crossref
Kaitlin Anstett, Vincent Cutillas, Robert Fusco, Thibault Mesplède & Mark A. Wainberg. (2016) Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. Journal of Antimicrobial Chemotherapy 71:8, pages 2083-2088.
Crossref
Crossref
Bluma G. Brenner, Réjean Thomas, José Luis Blanco, Ruxandra-Ilinca Ibanescu, Maureen Oliveira, Thibault Mesplède, Olga Golubkov, Michel Roger, Federico Garcia, Esteban Martinez & Mark A. Wainberg. (2016) Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. Journal of Antimicrobial Chemotherapy 71:7, pages 1948-1953.
Crossref
Crossref
Said A. Hassounah, Yannan Liu, Peter K. Quashie, Maureen Oliveira, Daniela Moisi, Bluma G. Brenner, Paul A. Sandstrom, Thibault Mesplède & Mark A. Wainberg. (2015) Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. Journal of Virology 89:23, pages 12002-12013.
Crossref
Crossref
Jannik Fonager, Jonas T. Larsson, Christian Hussing, Frederik Neess Engsig, Claus Nielsen & Thea Kølsen Fischer. (2015) Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing. Journal of Clinical Virology 73, pages 95-100.
Crossref
Crossref
Maureen Oliveira, Thibault Mesplède, Daniela Moïsi, Ruxandra-Ilinca Ibanescu, Bluma Brenner & Mark A. Wainberg. (2015) The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir. AIDS 29:17, pages 2255-2260.
Crossref
Crossref
Kaitlin Anstett, Robert Fusco, Vincent Cutillas, Thibault Mesplède & Mark A. Wainberg. (2015) Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. Journal of Virology 89:20, pages 10482-10488.
Crossref
Crossref
Isabelle Malet, Eloise Thierry, Marc Wirden, Samuel Lebourgeois, Frédéric Subra, Christine Katlama, Eric Deprez, Vincent Calvez, Anne-Geneviève Marcelin & Olivier Delelis. (2015) Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. Journal of Antimicrobial Chemotherapy 70:10, pages 2870-2880.
Crossref
Crossref
Agnès Depatureaux, Thibault Mesplède, Peter Quashie, Maureen Oliveira, Daniela Moisi, Jean-Christophe Plantier, Bluma Brenner & Mark A. Wainberg. (2015) HIV-1 Group O Resistance Against Integrase Inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes 70:1, pages 9-15.
Crossref
Crossref
Thibault Mesplède, Peter K. Quashie, Said Hassounah, Nathan Osman, Yingshan Han, Jiaming Liang, Diane N. Singhroy & Mark A. Wainberg. (2015) The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. AIDS 29:12, pages 1459-1466.
Crossref
Crossref
Thibault Mesplède & Mark Wainberg. (2015) Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses 7:7, pages 3703-3718.
Crossref
Crossref
John E. Tavis & Elena Lomonosova. (2015) The hepatitis B virus ribonuclease H as a drug target. Antiviral Research 118, pages 132-138.
Crossref
Crossref
Melissa Wares, Said Hassounah, Thibault Mesplède, Paul A. Sandstrom & Mark A. Wainberg. (2015) Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors. Antimicrobial Agents and Chemotherapy 59:4, pages 1942-1949.
Crossref
Crossref
Peter K. Quashie, Maureen Oliviera, Tamar Veres, Nathan Osman, Ying-Shan Han, Said Hassounah, Yolanda Lie, Wei Huang, Thibault Mesplède & Mark A. Wainberg. (2015) Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase. Journal of Virology 89:6, pages 3163-3175.
Crossref
Crossref
Agnès Depatureaux, Peter K. Quashie, Thibault Mesplède, Yingshan Han, Hannah Koubi, Jean-Christophe Plantier, Maureen Oliveira, Daniela Moisi, Bluma Brenner & Mark A. Wainberg. (2014) HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase. Antimicrobial Agents and Chemotherapy 58:12, pages 7141-7150.
Crossref
Crossref
Jay A. Grobler & Daria J. Hazuda. (2014) Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Current Opinion in Virology 8, pages 98-103.
Crossref
Crossref
Wan-Gang Gu. (2014) Newly approved integrase inhibitors for clinical treatment of AIDS. Biomedicine & Pharmacotherapy 68:8, pages 917-921.
Crossref
Crossref
Sophie Bastarache, Thibault Mesplède, Daniel Donahue, Richard Sloan & Mark Wainberg. (2014) Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency. Viruses 6:9, pages 3487-3499.
Crossref
Crossref